Construction of Samsung Biologics’ new facility is on track, with the CDMO saying pre-sales activities are ongoing for Plant 4, as it is known, despite the challenging business environment amid the COVID-19 pandemic.
Rentschler Biopharma and XL-protein have teamed up on the manufacture of what they say is a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I) that may open better treatment options for patients suffering from inflammation, chronic...
A clinical trial is exploring the use of the Oxford/AstraZeneca COVID-19 vaccine as an intranasal vaccine: seeing if the new route of administration could improve protection against infection and transmission.
Researchers at Stanford University and the University of North Carolina Chapel Hill are developing a microneedle vaccine patch that they believe could deliver a stronger immune response than a vaccine shot.
A lot has changed over the last year since IP waiver proposals were first put forward - notably a massive rise in the production of COVID-19 vaccines. Komal Kalha of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)...
Novartis has signed a new initial agreement with BioNTech for COVID-19 vaccine manufacturing: with its sterile manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
AION Labs, a new innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, has announced a global call for application to identify biomedical scientists and inventors to form a new startup at...
Locus Biosciences has entered a credit facility of up to US$25m with Hercules Capital, which it says will support the expansion of its precision engineered bacteriophage discovery platform engine and in-house manufacturing capacity.
Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.
The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.
Avid Bioservices, Inc. is expanding its CDMO service offering into the cell and gene therapy market: constructing a purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA.
LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.
CureVac is withdrawing its first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review: instead it is re-allocating its efforts to its second-generation vaccine program with GSK. ‘The goal has not changed, but the requirements to effectively...
AstraZeneca's AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
A probe has identified 'human error’ at the Spanish contract development and manufacturing organization, Rovi, as the reason for the presence of metal contaminants in Moderna COVID-19 vaccine doses, leading to Japanese authorities withdrawing 1.6...
M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.
Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.
The European Medicine Agency’s human medicines committee (CHMP) says that booster doses of the Pfizer/BioNTech vaccine may be considered in people aged 18+, although decisions on who is offered a booster will be made at a national level.
While several vaccines protect against meningitis, there remains an urgent need for innovation, funding and research to develop more meningitis-preventive vaccines, according to a new report from the WHO.